Biogen Idec Inc BIIB:NASDAQ (Common Stock)

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
389.16 35.91   10.17%4,029,7821.9M
Market data is delayed by at least 20 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Market is closed. As of 04:00 PM ET 1/30/2015

Latest News Headlines for Biogen Idec Inc

Biogen Idec 2014 Revenues Increase 40% to $9.7 -3-

Equity 10,814,040 8,620,838 ---------- ---------- TOTAL LIABILITIES AND EQUITY $ 14,316,559 $ 11,863,335

Biogen Idec 2014 Revenues Increase 40% to $9.7 -2-

The Company's earnings conference call for the fourth quarter will be broadcast via the internet at 4:30 p.m. EST on January 29, 2015, and will be accessible through the Investors section of Biogen Idec's homepage, Supplemental information in the form of a slide presentation will also be accessible at the same location on the internet at the time of the conference call and will be subsequently available on the website for at least one month.

Biogen Idec 2014 Revenues Increase 40% to $9.7 Billion

Performance led by continued growth in MS portfolio Four new treatments launched, including two in hemophilia, a new therapeutic area Pipeline programs advance in Multiple Sclerosis, Spinal Muscular Atrophy, and Alzheimer's Disease

View more recent headlines

Peers Information HelpBIIB Biogen Idec Inc vs. Peers

Biogen Idec Inc
Johnson & Johnson
Pfizer Inc.
Merck & Co., Inc.
AbbVie Inc
Biogen Idec Inc
Johnson & Johnson
Pfizer Inc.
Merck & Co., Inc.
AbbVie Inc
Biogen Idec Inc
Johnson & Johnson
Pfizer Inc.
Merck & Co., Inc.
AbbVie Inc
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings

This report contains detailed information about the company's business finances and management.


Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company’s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.


collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open372.75
Previous Close353.25
Day High397.00
Day Low372.75
52 Week HighToday | 397.00
52 Week Low4/15/2014 | 272.02
% Off 52 Week High-1.97%
% Off 52 Week Low43.06%
Beta (5 Yr)1.1
Volatility Avg1/30/2015 | 35.04
10-Day Avg. Volume1,862,810
Market data is delayed by at least 20 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)9/30/2014 | 10.57
P/E Ratio9/30/2014 | 33.4
Market CapLarge Cap | 91.9B
Shares Outstanding236.16M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short3.26M
Short Ratio1.6
Short % of Float1.38%
As of 1/15/2015